Treatment of pulmonary Mycobacterium avium complex infections: Do drug levels matter?

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 8, 2012, Pages 710-711

  Schluger, Neil W ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; ETHAMBUTOL; MACROLIDE; RIFABUTIN; RIFAMPICIN;

ATYPICAL MYCOBACTERIOSIS; DRUG BLOOD LEVEL; DRUG MONITORING; EDITORIAL; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG MONITORING; FEMALE; HUMANS; LUNG DISEASES; MALE; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION;

EID: 84867598380     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201208-1478ED     Document Type: Editorial

References (15)

1. Bodle EE, Cunningham JA, Della-Latta P, Schluger NW, Saiman L. Epidemiology of nontuberculous mycobacteria in patients without HIV infection, New York City. Emerg Infect Dis 2008;14:390-396. (Pubitemid 351451385)
2. Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med 2007;176:306-313. (Pubitemid 47195882)
3. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis 2010;16:1576-1583.
4. Chen CY, Chen HY, Chou CH, Huang CT, Lai CC, Hsueh PR. Pulmonary infection caused by nontuberculous mycobacteria in a medical center in Taiwan, 2005-2008. Diagn Microbiol Infect Dis 2012;72:47-51.
5. Winthrop KL, McNelley E, Kendall B, Marshall-Olson A, Morris C, Cassidy M, Saulson A, Hedberg K. Pulmonary nontuberculous mycobacterial disease prevalence and clinical features: an emerging public health disease. Am J Respir Crit Care Med 2010;182:977-982.
6. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
7. Wallace RJ Jr, Brown BA, Griffith DE. Drug intolerance to high-dose clarithromycin among elderly patients. Diagn Microbiol Infect Dis 1993;16:215-221. (Pubitemid 23107304)
8. Griffith DE, Brown BA, Girard WM, Wallace RJ Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 1995;21:594-598.
9. Parekh M, Kamelhar D, Schluger N. Nontuberculous mycobacterial infections in older patients. In: Pisani M, editor. Aging and lung disease: a clinical guide. New York: Springer; 2011. pp. 189-199.
10. Koh W-J, Jeong B-H, Jeon K, Lee S-Y, Shin SJ. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012;186:797-802.
11. van Ingen J, Egelund EF, Levin A, Totten SE, Boeree MJ, Mouton JW, Aarnoutse RE, Heifets LB, Peloquin CA, Daley CL. The pharmacokinetics and pharmacodynamics of pulmonary Mycobacterium avium complex disease treatment. Am J Respir Crit Care Med 2012;186:559-565.
12. Patel KB, Xuan D, Tessier PR, Russomanno JH, Quintiliani R, Nightingale CH. Comparison of bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. Antimicrob Agents Chemother 1996;40:2375-2379. (Pubitemid 26328049)
13. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-1402. (Pubitemid 27231452)
14. Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM, Daley CL, Catanzaro A. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2006;173:1283-1289. (Pubitemid 43848401)
15. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 2012;18:436-443.